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SUMMARY
Flexible endoscopy is a widely used diagnostic and therapeutic
procedure. Contaminated endoscopes are themedical devices fre-
quently associated with outbreaks of health care-associated infec-
tions. Accurate reprocessing of flexible endoscopes involves clean-
ing and high-level disinfection followed by rinsing and drying
before storage. Most contemporary flexible endoscopes cannot be
heat sterilized and are designed with multiple channels, which are
difficult to clean and disinfect. The ability of bacteria to form
biofilms on the inner channel surfaces can contribute to failure of
the decontamination process. Implementation of microbiological
surveillance of endoscope reprocessing is appropriate to detect
early colonization and biofilm formation in the endoscope and to
prevent contamination and infection in patients after endoscopic
procedures. This review presents an overview of the infections and
cross-contaminations related to flexible gastrointestinal endos-
copy and bronchoscopy and illustrates the impact of biofilm on
endoscope reprocessing and postendoscopic infection.
INTRODUCTION
The consequences of the use of contaminated endoscopes area recurrent topic in the endoscopy literature. Flexible en-
doscopes may become heavily contaminated with blood, secre-
tions, and microorganisms during use. These instruments are
difficult to clean and disinfect and easy to damage because of
their complex design, with narrow lumens and multiple inter-
nal channels (Fig. 1) (1). If the instruments are not properly
cleaned, the disinfection and drying procedures can fail and
increase the possibility of transmission of infection from one
patient to another (2). In addition, the ability of bacteria to
form biofilms in the endoscope channels, especially when these
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become damaged, can contribute to failure of the decontami-
nation process (2, 3).
Accurate reprocessing of flexible endoscopes is a multistep
procedure involving cleaning followed by high-level disinfection
(HLD) with further rinsing and drying before storage. Endoscope
reprocessing can be performed with the use of automated endo-
scope reprocessors (AERs) and manual methods. Since almost all
outbreaks are related to breaches in reprocessing techniques, it is
crucial that endoscope cleaning, disinfection, and drying are per-
formed according to a strict protocol. However, process control of
endoscope reprocessing does not guarantee prevention of settle-
ment of biofilm during endoscopy (2).
Current endoscope reprocessing and infection control guide-
lines have been reported by various organizations (4–7), and un-
der controlled conditions, these measures are adequate. The most
common factors associated with microbial transmission involve
inadequate cleaning, disinfection, and drying procedures; the use
of contaminated AERs; and flaws in instrument design or the use
of damaged endoscopes.
Endoscopy-related infections can be divided into two types:
endogenous and exogenous. Endoscopic procedures most often
result in endogenous infections (i.e., infections resulting from the
patient’s ownmicrobial flora), and Escherichia coli,Klebsiella spp.,
Enterobacter spp., and enterococci are the species most frequently
isolated (8). Examples of endogenous infections include pneumo-
nia resulting from aspiration of oral secretions in a sedated patient
during flexible bronchoscopy and bacteremia in patients with bil-
iary obstruction during endoscopic retrograde cholangiopancrea-
ticography (ERCP). Endogenous infections are associated with
endoscopy but cannot be prevented by well-controlled disinfec-
tion procedures (9). The exogenous microorganisms most fre-
quently associated with transmission are Pseudomonas aeruginosa
and Salmonella spp. during flexible gastrointestinal (GI) endos-
copy and P. aeruginosa and mycobacteria during bronchoscopy
(10). These microorganisms can be transmitted from previous
patients or contaminated reprocessing equipment by contami-
nated endoscopes or its accessory equipment. Exogenous infec-
tion should be prevented by strict endoscope disinfection proce-
dures (9).
The purpose of this review is to present an overview of the
infections and cross-contaminations related to flexible GI endos-
copy and bronchoscopy and to illustrate the impact of biofilm on
endoscope reprocessing and postendoscopic infection.
PRACTICAL ASPECTS OF FLEXIBLE ENDOSCOPE
REPROCESSING
Relevance of Cleaning and Disinfection
According to the Spaulding classification system, medical devices
are divided into three categories based on the risk of infection
(11). Critical medical instruments (e.g., surgical instruments and
prosthetic heart valves) that enter the vascular system and nor-
mally sterile tissues and that carry a high degree of infection risk if
contaminated during use should be sterilized. Noncriticalmedical
devices, such as stethoscopes, coming into contact with intact skin
require low-level disinfection or simple cleaning with detergent
andwater.Most flexible endoscopes belong to semicritical devices
which come into contact withmucousmembranes during use and
have a moderate degree of infection risk if contaminated at the
time of use. They should receive at least HLD. HLD is a process
that eliminates or kills all vegetative bacteria, mycobacteria, fungi,
and viruses, except for small numbers of bacterial spores (12, 13).
Sterilization results in the complete destruction of all forms of
microbiological life, including bacterial spores.
Flexible endoscopes for therapeutic procedures (bronchoscopy
and ERCP) and reusable accessories, such as biopsy forceps, are
used in sterile body cavities and should be classified as critical
devices (12, 13). They should be sterilized after each procedure.
Due to their material composition, most flexible endoscopes can-
not be steam sterilized (9). They tolerate ethylene oxide and hy-
drogen peroxide plasma sterilization, which are expensive and are
not preferred bymost institutions (14).Nodata are available dem-
onstrating that sterilization results in a lower frequency of posten-
doscopic infection than does HLD. Ethylene oxide and hydrogen
peroxide plasma sterilization have rapid and reliable efficacy com-
pared to HLD (15). However, both sterilizers destroy chemical,
biological, and mechanical properties of instruments, including
flexible endoscopes. Gas sterilization with ethylene oxide may fail
in the presence of organic debris after inadequate cleaning (16, 17)
and when biofilm has settled in internal endoscope channels
(2, 18).
Natural bioburden levels detected on flexible GI endoscopes
range from 105 CFU/ml to 1010 CFU/ml after clinical use (19, 20).
Cleaning must precede HLD or sterilization to remove organic
debris (e.g., blood, feces, and respiratory secretions) from the ex-
ternal surface, lumens, and channels of flexible endoscopes (4,
21). Inadequate cleaning of flexible endoscopes has been fre-
quently associated with microbial transmission during endo-
scopic procedures. Appropriate cleaning reduces the number of
microorganisms and organic debris by 4 logs, or 99.99% (20).
The manual cleaning procedure for flexible endoscopes in-
cludes brushing of the external surface and removable parts (e.g.,
FIG 1 Schematic drawing of a cross section of a flexible endoscope showing
the complex design and multiple internal channels (inner diameter, 2.8 to 3.8
mm).
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suction valves) and immersion in a detergent solution followed by
irrigation of internal channels with a detergent. The endoscope
and accessories should be inspected for damage, and a leak test
should be performed before disinfection (4).
AERs are strongly recommended for reprocessing of flexible
endoscopes to document all steps and tominimize contamination
and contact with chemicals and contaminated instruments (5).
However, contaminated and defective AERs can result in inade-
quate reprocessing and contamination of endoscopes and have
been associated with outbreaks of endoscopy-related infections
(22–26). Presence of biofilms in the AERs has been detected dur-
ing these outbreaks (23, 25, 26).
Disinfecting agents used for HLD must have bactericidal, my-
cobactericidal, fungicidal, virucidal, and sporicidal activity (12,
13). According to their activity against bacteria, fungi, spores, and
viruses, disinfectants can be classified into the following three
groups: high-level (glutaraldehyde, peracetic acid, and ethylene
oxide), intermediate-level (ethanol, formaldehyde, and phenolic
solutions), and low-level (povidone-iodine, cetrimide, and ben-
zalkonium chloride) disinfectants (11, 12, 27). Intermediate-level
disinfectants do not have sporicidal activity. Disinfectants with
low potency do not destroy Mycobacterium tuberculosis, atypi-
cal mycobacteria, and bacterial spores. Concentration and ex-
posure time of a disinfecting agent are crucial; inappropriate
dilution and insufficient exposure can result in a failure of
effective reprocessing (28–30). Inappropriate disinfectants
with low and intermediate potency are not recommended for
HLD and have been replaced by glutaraldehyde, hydrogen per-
oxide, ortho-phthalaldehyde, peracetic acid, and superoxidized
and electrolyzed acid water (31, 32). Advantages and disadvan-
tages of commonly used high-level disinfectants are summa-
rized in Table 1.
Glutaraldehyde (2 to 4%) is a disinfecting agent effective against
bacteria, viruses, fungi, and spores that is relatively inexpensive, is
noncorrosive tometal, and does not damage endoscopes and pro-
cessing equipment (5, 33). Two percent aqueous solutions of glu-
taraldehyde killed vegetative bacteria in2min, fungi and viruses
in10min, and spores ofBacillus spp. andClostridium spp. in 3 h
(33–35). However, glutaraldehyde has irritant properties for the
respiratory tract, eyes, and skin and can cause allergic reactions,
contact dermatitis, and asthma (36). For these reasons, the use of
this high-level disinfectant should be done with containment to
minimize aerosolization of glutaraldehyde. Acute colitis occur-
ring after lower GI endoscopy was probably caused by glutaralde-
hyde residues in the endoscope after disinfection (37). Other dis-
advantages of glutaraldehyde are coagulation and fixation of
proteins and failure to eliminate atypical mycobacteria within
standard contact times (5, 35, 38).
Microorganisms possessing resistance to glutaraldehyde in-
clude atypical mycobacteria (Mycobacterium chelonae and Myco-
bacterium avium complex) (39, 40) and Cryptosporidium parvum
(41). P. aeruginosa resistance to glutaraldehyde was responsible
for three separate clinical episodes of ERCP-associated cholangitis
(42). The mechanism of the high biocide resistance of mycobac-
teria is probably associated with the decreased penetration of a
disinfectant through the hydrophobic lipid-rich cell wall (35).
Two percent alkaline glutaraldehyde completely inactivated M.
tuberculosis in bronchoscopes after 10 min of incubation (43).M.
avium, Mycobacterium gordonae, and Mycobacterium intracellu-
larewere more resistant to inactivation by 2% alkaline glutaralde-
hyde and survived the treatment for more than 10min (38). Since
mycobacteria aremore resistant to glutaraldehyde than other bac-
teria, the manufacturers’ instructions for flexible endoscopes and
this high-level disinfectant should followed to determine the cor-
rect conditions.
ortho-Phthalaldehyde (0.55%) is a high-level disinfectant with a
TABLE 1 Advantages and disadvantages of commonly used high-level disinfectants
High–level
disinfectant Advantage(s) (reference[s]) Disadvantage(s) (reference[s])
Glutaraldehyde Excellent biocidal properties (5, 33–35) Slow action against mycobacteria (35, 38)
Many studies published Irritant to the respiratory tract, eyes, and skin; development
of allergic reactions, contact dermatitis, asthma, acute
colitis (36, 37)
Does not damage endoscopes and processing equipment;
noncorrosive to metal (5, 33)
Development of biocide resistance (39–42)
Relatively inexpensive (5) Coagulation and fixation of proteins (5)
ortho-Phthalaldehyde High biocidal activity (inclusive of mycobacteria) (5, 44) Slow action against bacterial spores (5)
Does not damage endoscopes and processing equipment Staining of the skin, clothing, instruments (46)
Irritation of the respiratory tract and eyes; development of
“anaphylaxis-like” reactions after repeated use (5, 36, 45)
Expensive
Peracetic acid Excellent and fast biocidal activity at low concentrations (5, 7) Irritant to the respiratory tract and eyes (5, 7, 36)
Can be used at low temperatures (5, 7) Corrosive action depending on the pH value and concn (7)
No development of resistance reported Limited efficacy in biofilm removal and in killing bacteria
within the biofilm (47–49)
Electrolyzed acid and
superoxidized water
Excellent and fast biocidal activity (15) Reduced efficacy in the presence of organic soil after
inappropriate cleaning (50)Nontoxic to biological tissues; nonirritant to the respiratory
tract, eyes, and skin (15)
Relatively inexpensive
Transmission of Infection by Flexible Endoscopy
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higher mycobactericidal efficacy than glutaraldehyde (5, 44). Dis-
advantages of this disinfectant include slow action against bacte-
rial spores, irritation of the respiratory tract and eyes of the pa-
tients and staff, and the possibility of causing “anaphylaxis-like”
reactions after repeated use (5, 36, 45). ortho-Phthalaldehyde
stains skin, instruments, clothing, and surfaces and ismore expen-
sive than glutaraldehyde (46).
Peracetic acid is an oxidizing agent usually used for HLD of
flexible endoscopes in AERs. It rapidly deactivates a large variety
of pathogenicmicroorganisms, viruses, and spores at low concen-
trations (0.3%) (5, 7). No development ofmicroorganism resis-
tance to peracetic acid has been reported. This disinfectant can be
used at low temperatures and causes less irritation than glutaral-
dehyde but has corrosive action depending on the pH value and
concentration (7). Several disinfectants that contain peracetic acid
and hydrogen peroxide are available. Although the biocidal effect
of peracetic acid on sessile microorganisms is well known, the
effect of this disinfecting agent onmicrobial biofilms has not been
completely studied. A recent study demonstrated insufficient ef-
ficacy of 1% peracetic acid disinfectant for 10 min against P.
aeruginosa, Stenotrophomonas maltophilia, and Candida sp. bio-
films (47). According to the literature, peracetic acid has the abil-
ity to fixate biofilms, and therefore, it can show limited efficacy in
biofilm removal from the abiotic surfaces and in killing bacteria
within the biofilm (48, 49). Vigorous cleaning with brushes or
agitated liquids is important to remove as much biofilm as possi-
ble (4).
Electrolyzed acid and superoxidized water are relatively new
disinfectants used for endoscope reprocessing (15). These disin-
fectants are produced by the electrolysis of sodium chloride solu-
tions. They have excellent biocidal activity and are inexpensive,
nontoxic to biological tissues, and nonirritating to the respiratory
tract, eyes, and skin (15). However, antimicrobial efficacy can be
reduced in the presence of organic soil after inappropriate clean-
ing (50).
After the disinfection phase, the remaining disinfectantmust be
removed from the exterior and from the internal channels by rins-
ing the endoscope with bacterium-free water. According to the
Guideline Committee of the European Society of Gastrointestinal
Endoscopy, sterile water is preferable for the final rinse to prevent
recontamination (5).Many outbreaks of endoscopy-related infec-
tions and cross-contaminations due to P. aeruginosa, Serratia
marcescens, M. chelonae, Mycobacterium xenopi, and Methylobac-
terium mesophilicum have been related to rinsing flexible endo-
scopes after disinfection with nonsterile tap water (30, 51–57).
The accepted procedures to produce bacterium-free water in dis-
infectors for endoscopes include filtration, UV radiation, or heat-
ing followed by cooling (5). However, major U.S. guidelines rec-
ommend the use of sterile, filtered, or tap water to rinse the
endoscope channels after HLD, followed by flushing of the endo-
scope channels with 70% to 90% ethyl alcohol or isopropyl alco-
hol (6, 7, 21). The rinse water must be discarded after each cycle.
Water bottles used for irrigation during the procedure should be
high-level disinfected or sterilized at least daily. Sterile water
should be used to fill the water bottle.
Relevance of Drying and Storage
Accurate endoscope drying is crucial, whereas a humid environ-
ment facilitates microbial growth during storage. The final drying
steps greatly reduce the risk of remaining pathogens as well as the
possibility of recontamination of the endoscope by waterborne
microorganisms such as Pseudomonas spp. and Acinetobacter spp.
(58). Flexible endoscopes should be dried with filtered com-
pressed air manually or in AERs between endoscopic procedures
(a short drying cycle) and at the end of the day (an intensive final
drying) (5, 59). Several guidelines recommend forced air drying,
preceded by flushing of the internal channels with 70% to 90%
ethanol or isopropanol at the end of a clinic day (6, 7, 21). Allen et
al. (22) showed a high efficiency in preventing P. aeruginosa con-
taminations by flushing 70% ethanol through endoscope chan-
nels followed by drying with compressed air. Due to the fixative
properties of ethanol, its use is not recommended in some coun-
tries.
Storage is an important factor in themaintenance of bacterium-
free endoscopes. It is recommended that a dust-free drying cabi-
net be used for endoscope storage, in which the endoscopes are
hung vertically (5, 60, 61). Noy et al. (62) noted that storing the
endoscopes vertically in air after cleaning until the next use of the
endoscope resulted in a drop of the contamination rate from 35 to
0%. According to the literature, endoscopes stay bacterium free
after prolonged storage if an adequate drying procedure is applied
(60, 61).When stored in the drying cabinet with a laminar airflow,
no growth of bacteria and Candida spp. was found in endoscope
channels 5 days after reprocessing (61). Low levels of microbial
contamination on endoscopes stored in the drying and storage
cabinet were detected, compared with the stable or increased mi-
crobial numbers on endoscopes stored outside the cabinet (60).
Many outbreaks of health care-associated infection after endos-
copy and cross-contaminations due to P. aeruginosa, S. marc-
escens,M. tuberculosis, andM. chelonae have been associated with
drying of flexible endoscopes without ethanol flushing or lack of a
drying procedure (22–24, 30, 52, 57, 63–76).
EXOGENOUS INFECTIONS ASSOCIATED WITH FLEXIBLE
ENDOSCOPY
Despite the large number of endoscopic procedures that are per-
formed annually, documented data suggest that postendoscopic
iatrogenic infections are rare. In GI endoscopy, the estimated rate
of health care-associated infection is approximately 1 out of 1.8
million procedures (77). However, the true rate of transmission
during endoscopy may go unrecognized because of technically
inadequate surveillance, no surveillance at all, low frequency, or
the absence of clinical symptoms (2, 9). Two hundred eighty-one
patients infected after GI endoscopy were found in studies of en-
doscopy-related infections between 1966 and 1992 in the United
States (8). Gorse and Messner (14) reported 6% iatrogenic infec-
tions after GI endoscopy in 116 hospitals. During the period of
1974 to 2004, 30 outbreaks of endoscopy-related infections and
cross-contaminations involving 251 patients infected after GI en-
doscopic procedures were reported in the United States (78). In-
adequate decontamination procedures and equipment malfunc-
tion were two leading causes of postendoscopic infection and
contamination. More than 91% of the infections identified could
be prevented if quality control systems were improved.
The important risk factors of infections in GI endoscopy are
the number of microorganisms present inside the endoscope or
the growth of a biofilm, invasive endoscopic procedures resulting
in tissue damage, compromised immune status of the patient (hu-
man immunodeficiency virus [HIV] infection, neoplastic dis-
eases, transplant patients, and immunosuppressive treatment),
Kovaleva et al.
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and the presence of infective foci (abscess and cholangitis) during
an endoscopic procedure (79–81).
An overview of the exogenous endoscopy-related infections
and cross-contaminations after flexible GI endoscopy and bron-
choscopy is presented in Tables 2 to 5.
Bacteria
Salmonella spp. In the past, Salmonella spp. were the most com-
monmicroorganisms associatedwith infections transmitted byGI
endoscopy (28, 82–88). Many Salmonella outbreaks were related
to an inappropriate use of disinfectants with intermediate and low
potency instead of high-level disinfecting agents (Tables 2 and 3).
There have been no reports of Salmonella infection since the cur-
rent guidelines for HLD have been followed.
The following Salmonella serotypes were isolated from con-
taminated endoscopes or accessories: Salmonella enterica sero-
types Typhi (84), Typhimurium (28, 82), Agona (88), Goerlitz
(28),Newport (85),Oslo (83), Kedougou (86), and Lomita (87). A
minority of patients involvedwere asymptomatic carriers and had
stool or urine cultures positive for Salmonella spp. Salmonella in-
fections developed within 1 to 9 days after a GI endoscopic proce-
dure and included acute gastroenteritis (28, 82, 83, 85, 86), peri-
toneal abscess (82), urinary tract infection (28), and bacteremia/
sepsis (83, 84, 88).
Pseudomonas aeruginosa. P. aeruginosa, a Gram-negative op-
portunistic pathogen, is the most commonly reported microor-
ganism responsible for transmission of infection duringGI endos-
copy and bronchoscopy. It is known for its preference for a moist
environment (hospital water supply and wet endoscope channels
after reprocessing) (10).Pseudomonas is able to formbiofilms, and
these biofilms are extremely difficult to remove from plumbing,
AERs, and endoscope channels (2, 89). Serotype 10 of P. aerugi-
nosa predominates in the published reports ofPseudomonas trans-
mission (22, 23, 53, 73, 90, 91). It is possible that slime production
by P. aeruginosa serotype 10 in a biofilm can form a barrier to
antibiotics and disinfectants and lead to antibacterial resistance,
but no explanation was offered as to why specifically this serotype
was isolated.
Among healthy adults, P. aeruginosa can colonize many body
sites, as evidenced by isolation from throat, sputum, and stool
(92). Hospitalized patients, as well as patients with certain chronic
lung diseases, have higher colonization rates. During health care-
related outbreaks, Pseudomonas transmission can result in coloni-
zation of involved patients in the GI and respiratory tract with an
absence of clinical symptoms and negative blood cultures, which
was determined by molecular typing (93). Severe health care-as-
sociated postendoscopic infections due to P. aeruginosa include
sepsis, liver abscess, and ascending cholangitis after flexible GI
endoscopy (particularly after ERCP) and bloodstream infection
and pneumonia after bronchoscopy. Post-ERCP P. aeruginosa in-
fectious complications occur most frequently in patients with bil-
iary obstruction undergoing endoscopic biliary stenting (94).
Many outbreaks of P. aeruginosa infection after GI endoscopy
and bronchoscopy have been associated with inadequate cleaning
and the use of inappropriate intermediate-level and low-level dis-
infectants (29, 62, 64, 73, 80, 90, 95–98), contaminated endoscope
water bottles and thewater supply to the endoscope (29, 65, 90, 99,
100), and drying of endoscope channels with no flushing with
70% ethanol after disinfection (22, 30, 70, 73–75) or lack of a
drying procedure (26, 64) (Tables 2 to 5). Two recent outbreaks of
multidrug-resistantP. aeruginosa post-ERCP infections have been
related to the remaining contamination of the endoscope despite
accurate reprocessing followed by negative surveillance endo-
scope cultures (2, 101). In an outbreak of post-ERCP sepsis de-
scribed byKovaleva et al. (2), the implicated endoscopewas repet-
itively found to be positive by culturing for multidrug-resistant P.
aeruginosa after HLD and contained biofilm in undamaged inner
channels. The P. aeruginosa isolates from patients and the impli-
cated endoscope underwentmolecular typing and showedmatch-
ing patterns.
Several postendoscopic P. aeruginosa outbreaks have been re-
lated to contaminated or defective AERs (22, 23, 26, 74, 75, 102,
103), the use of incorrect connectors between the endoscope and
AER (103, 104), and defective endoscopes and accessories (93,
105–107) (Tables 2 to 5). The presence of biofilm deposits on the
internal plumbing and detergent tank of AERs resulted in two
outbreaks (23, 26).
In most outbreaks, the Pseudomonas strains obtained from pa-
tients were identical to those recovered from endoscopes, as de-
termined by comparison of antimicrobial sensitivity patterns of
the isolates, serotyping, and phage typing or by more recently
developed molecular techniques (90, 97).
Mycobacteria.M. tuberculosis and nontuberculous mycobac-
teria are microorganisms frequently associated with health
care-associated transmission during endoscopic procedures,
particularly during bronchoscopy. While transmission of non-
tuberculous mycobacteria is usually associated with contami-
nated AERs and rinsing water, contamination withM. tubercu-
losis generally comes from an infected patient during an
endoscopic procedure (8). Most outbreaks due to nontubercu-
lous mycobacteria have involved rapidly growing M. chelonae,
intermediately growing M. gordonae, and slowly growing M.
xenopi and M. avium complex strains.
Most publications about mycobacterial outbreaks described
cross-contamination, a situationwhere the patient becomes noso-
comially colonized with a strain from the endoscope in the ab-
sence of infection, but reports of bronchoscopy-related pulmo-
nary tuberculosis were documented (63, 108–111). The majority
of the patients was immunocompromised and had a history of
lung cancer, HIV, or hematological malignancies. MostM. tuber-
culosis isolates were susceptible to antituberculosis drugs, but
health care-associated transmission of multidrug-resistant tuber-
culosis has been reported (63). Nontuberculous mycobacteria,
such as M. chelonae, M. avium, M. xenopi, M. gordonae, and M.
fortuitum, can form the risk for development of colonization or
infection in severely immunocompromised patients (112, 113).
The effectiveness of disinfectants against mycobacteria de-
pends on the composition and concentration of the active agent,
contact time, and presence of organic material (27, 113, 114).
Activities of different disinfectants against M. tuberculosis and
nontuberculous mycobacteria were tested in several studies. van
Klingeren and Pullen (115) showed inadequate tuberculocidal ac-
tivity of quaternary ammonium, good activity of phenolic disin-
fectants, and rapid killing ofM. tuberculosiswith 70% ethanol and
60% isopropanol. High-level effectiveness of 2% glutaraldehyde
againstM. tuberculosis andM. chelonaewas demonstrated directly
after cleaning and after 10- and 20-min exposures (43, 116, 117).
Peracetic acid (0.26%)was effective againstM. tuberculosis andM.
avium complex strains within 10 to 20min, with a 5-log reduction
in viable bacteria (118).
Transmission of Infection by Flexible Endoscopy
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Mycobacteria are known to possess resistance to many disin-
fecting agents, including aldehydes (35, 119). The mechanism of
the high-level biocide resistance ofmycobacteria is not completely
understood; most likely, it is associated with decreased penetra-
tion of a disinfectant through the hydrophobic lipid-rich cell wall
(35). Nontuberculous mycobacteria tend to be more resistant to
antiseptics and disinfectants than M. tuberculosis (113). Slow-
growing M. avium complex and intermediately growing M. gor-
donae strains survived treatmentwith 2%glutaraldehyde formore
than 10 min (38). The M. chelonae strain resistant to glutaralde-
hyde and peracetic acid was isolated from a contaminated AER
(40). Nomura et al. (39) reported a high percentage of glutaralde-
hyde-tolerant M. chelonae strains which were either resistant or
intermediately resistant to 2 or 3 classes of antibiotics.
Most outbreaks of M. tuberculosis and nontuberculous myco-
bacterium transmission have been associated with inadequate











contamination Cause(s) of contamination
87 Salmonella Lomita 2 0 No Not tested Inappropriate cleaning and disinfection
(phenolic solution)
28 Salmonella Goerlitz 1 1 Gastroenteritis Yes Lack of manual cleaning; inappropriate
disinfection (phenolic solution)
85 Salmonella Newport 8 2 Gastroenteritis Yes Biopsy forceps not sterilized; inappropriate
disinfection (iodophor solution)
181 HCV 2 2 HCV infection Not tested Inadequate manual cleaning; insufficient
disinfectant exposure; biopsy forceps
not sterilized
182 HCV 1 1 HCV infection Not tested Contaminated syringe or anesthetic vial;
inappropriate disinfection











contamination Cause(s) of contamination
95 P. aeruginosa 1 1 Cholangitis, sepsis Yes Inappropriate cleaning and disinfection (ethanol)
96 P. aeruginosa 14 0 No Yes Inappropriate cleaning and disinfection
(povidone-iodine/ethanol)
97 P. aeruginosa 7 7 Cholangitis Yes Inappropriate cleaning and disinfection (ethanol)
100 P. aeruginosa 1 1 Sepsis Yes Contaminated water bottles
53 P. aeruginosa 4 3 Sepsis Yes Inappropriate disinfection; rinsing with nonsterile
tap water
91 P. aeruginosa 5 5 Cholangitis, sepsis, urinary
tract infection
Yes Inadequate cleaning and disinfection between uses
in patients (tap water)
22 P. aeruginosa 10 5 Cholecystitis, liver abscess Yes Contaminated AER; inappropriate cleaning and
disinfection; drying with no ethanol flushing
328 P. aeruginosa 1 1 Liver abscess No Not found; endoscope reprocessing not described
98 P. aeruginosa 2 2 Sepsis Yes Inappropriate cleaning and disinfection (cetrimide)
90 P. aeruginosa 7 7 Bacteremia/sepsis,
cholangitis, pancreatitis
Yes Contaminated water bottle; inadequate manual
cleaning and disinfection between patients
(isopropanol)
99 P. aeruginosa 5 5 Sepsis Yes Contaminated water bottle (not disinfected)
23 P. aeruginosa 16 No data Bacteremia/sepsis,
cholangitis, pneumonia
Yes Contaminated AER (a flaw in design, presence of
biofilm); drying with no ethanol flushing
75 P. aeruginosa 25 25 Bacteremia/sepsis Yes Failure to disinfect elevator channel in AER; drying
with no ethanol flushing
101 P. aeruginosa 5 3 Cholangitis, sepsis No Not found; endoscope reprocessing not described
29 P. aeruginosa 3 3 Sepsis Yes Contaminated water bottle; inadequate manual
cleaning; insufficient disinfectant exposure
2 P. aeruginosa 3 3 Sepsis Yes Presence of biofilm in intact endoscope channels
83 Salmonella Oslo 3 2 Gastroenteritis, sepsis Not tested Inappropriate cleaning and disinfection
(povidone-iodine/ethanol)
141 Serratia marcescens 1 0 No Yes Inappropriate cleaning and disinfection
(povidone-iodine)
52 M. chelonae 14 0 No No data Contaminated AER; inappropriate disinfection;
rinsing with tap water; lack of drying procedure
147 Methylobacterium mesophilicum 1 1 Bacteremia Yes Contaminated endoscope channels
144 ESBL-producing K. pneumoniae 16 12 Bacteremia/sepsis,
cholangitis
Yes Contaminated endoscope channels; insufficient
drying procedure
145 KPC-producing K. pneumoniae 7 2 Bacteremia Yes Contaminated endoscope channels; insufficient
drying procedure
184 HCV 1 1 HCV infection Not tested Inadequate disinfection (low concn, insufficient
exposure); failure to perfuse elevator channel
a AER, automated endoscope reprocessor; ESBL, extended-spectrum -lactamase; KPC, Klebsiella pneumoniae carbapenemase.
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cleaning, disinfection, and drying procedures (24, 27, 51, 52, 63,
66, 68, 71, 76, 104, 108, 109, 120), contaminated AERs and con-
taminated tap water used to rinse bronchoscopes after disinfec-
tion (24, 25, 51, 52, 56, 68, 71, 76, 121–123), and defective or
contaminated endoscopes and accessories (104, 110, 111, 120,
124–127) (Tables 4 and 5). The presence of M. chelonae and M.
mesophilicum biofilms was found in a contaminated AER during
one outbreak (25).
Helicobacter pylori. Although Helicobacter pylori is a common
pathogen in patients with chronic gastritis, peptic ulcer, and gas-
tric cancer, transmission of H. pylori by GI endoscopy is rare.
Langenberg et al. (128) documented a 1.1% risk of endoscopic
transmission of H. pylori in patients. Tytgat (129) estimated the
frequency of transmission to be approximately 4 per 1,000 endo-
scopic procedures when the infection rate in the population was
about 60%. However, the true incidence ofH. pylori transmission
may be underestimated because of the high prevalence of Helico-
bacter infection in the examined patient population and the
asymptomatic or nonspecific clinical presentation ofH. pylori in-
fection (129).
H. pylori transmission was recognized with the introduction of
new molecular techniques and was first demonstrated by using
restriction enzyme DNA analysis (128, 130). Three H. pylori out-
breaks after upper GI endoscopy were related to inadequate re-
processing of endoscopes and not-sterilized biopsy forceps (128,
130, 131). Four patients involved in these outbreaks developed
postendoscopic gastritis.
Although H. pylori is readily killed by most disinfectants, in-
cluding glutaraldehyde, povidone-iodine, and benzalkonium
chloride, within 15 to 30 s (132), 70% ethanol failed to disinfect
endoscopes between uses in patients (128). Disinfection with 2%
glutaraldehyde for 5 and 10 min was effective in eliminating H.
pylori DNA from flexible endoscopes (133, 134).
Clostridium difficile. C. difficile, an obligatory anaerobic,
spore-forming, Gram-positive rod, is responsible for a number of
different intestinal diseases and is transmitted from patient to pa-
tient through the oral ingestion of its vegetative cells or en-
dospores (135). Only one report of possible C. difficile transmis-
sion with development of fulminant pseudomembranous colitis
after colonoscopy has been published (136). Thus, the risk of de-
velopment of C. difficile-associated diarrhea after GI endoscopy is
very low (137).
Commonly used high-level disinfectants have been studied to
assess whether the vegetative cells and endospores ofC. difficile are
destroyed during different exposure times. Two percent glutaral-
dehyde and peracetic acid are capable of destroying large numbers
of C. difficile endospores using exposure times of 5 to 20 min
(138–140).
Other microorganisms. Many health care-associated S. marc-
escens outbreaks have been related to inadequate disinfection and
drying procedures (30, 55, 57, 72, 141, 142) and rinsing of endo-
scope channels with nonsterile tap water after disinfection (30, 55,
57) (Tables 4 and 5). A postbronchoscopic outbreak involved 117
patients who were colonized with different Enterobacteriaceae and
was associated with two specific bronchoscopes contaminated
with Klebsiella pneumoniae and Proteus vulgaris (143).
Duodenoscope-related nosocomial infections due to extend-
ed-spectrum--lactamase (ESBL)-producing and K. pneumoniae
carbapenemase (KPC-2)-producingK. pneumoniae have been de-
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producing ESBL type CTX-M-15 was isolated from patients with
post-ERCP sepsis and cholangitis (144). One duodenoscope was
indicated as the source of patient-to-patient transmission. Envi-
ronmental cultures from the AERs and surfaces of the endoscopy
rooms and routine surveillance cultures from endoscopes were
negative. In the second outbreak, transmission of KPC-2-produc-
ing K. pneumoniae was associated with the use of a contaminated
duodenoscope that had previously been used to examine an index
patient transferred from a Greek hospital (145). An incomplete
drying procedure was detected during endoscope reprocessing.
Methylobacterium is a slow-growing, pink-pigmented, Gram-
negative rod and is a common contaminant in water (146). Cross-
contaminations ofMethylobacterium in patients by contaminated
bronchoscopes have been related to contaminated tapwater in the
bronchoscopy unit and to biofilm-containing AERs (25, 54). It
was considered a colonizer because no patient manifested true
infection with this bacterium. Only one case ofMethylobacterium
bacteremia in a patient after ERCP and removal of a biliary tract
prosthesis has been reported (147).Methylobacterium has a strong
biofilm-producing ability and is highly resistant to dehydration,
elevated temperatures, and ionizing radiation, which can explain
the frequent occurrence and colonization ofMethylobacterium in
the hospital environment (148, 149).
A wide variety of other pathogens can be transmitted during
endoscopic procedures. Health care-associated transmission of
Strongyloides stercoralis (150), Trichosporon spp. (151, 152), and
the yeast Rhodotorula rubra (69, 153) have been reported. Cross-
contaminations of Blastomyces dermatitidis (154), Legionella
pneumophila (155), and Bacillus spp. (156) after flexible bron-
choscopywere related to inadequate cleaning anddisinfection and
a contaminated suction valve of the instrument.
The sensitivity of many unusual pathogens to disinfecting
agents ismainly unknown. La Scola et al. (157) reported that HLD
with 2% glutaraldehyde or peracetic acid disinfectants for 20 min
may be ineffective to prevent transmission of Tropheryma whip-
plei by GI endoscopes. According to Muscarella (158), 2% glutar-
aldehyde and gas sterilization with ethylene oxide are able to de-
stroy the vegetative cells and endospores of Bacillus anthracis.
Transmissible cysts of intestinal protozoa such as Giardia intesti-
nalis and Cryptosporidium are highly resistant to many disinfec-
tants, including chlorine (159) and 2% glutaraldehyde (160).
Viruses
Hepatitis B virus. Hepatitis B virus (HBV) is a highly infectious
DNAvirus that is easily transmitted through contactwith blood or
body fluids of an infected person. Despite the high infectivity of
hepatitis B, only one case of endoscopic HBV transmission con-
firmed by molecular analysis has been documented after gastros-
copy (161). Two other reports describedHBV transmission in two
patients after GI endoscopy with an instrument used in HBV-
positive patients (162, 163). Both patients becameHBsAg positive
9 months after endoscopy. Subtyping of the virus was not per-
formed. The implicated endoscopeswere inadequately disinfected
between procedures.
Several clinical studies monitored patients after GI endoscopic
procedures performedwith an endoscope used during a preceding
procedure in HBV-positive patients (164–171). No evidence of
subsequent HBV infection related to the previous endoscopy was
found, confirming that HBV transmission is not associated with
GI endoscopy when appropriate disinfection procedures are per-
formed.
Two studies have examined the sensitivity of HBV to disinfec-
tants, including 2% glutaraldehyde at 20°C for 10 min and 80%
ethanol at 11°C for 2 min, and heating at 98°C for 2 min (172,
173). All treatments were shown to be effective, indicating that the
resistance level of HBV is not extreme.
HepatitisC virus.HepatitisC virus (HCV) is a small, enveloped
RNA virus that can be transmitted through contact with infected
blood or body fluids during diagnostic and therapeutic invasive
procedures (174). The overall risk for HCV transmission through
GI endoscopy is controversial. Several studies found that GI en-
doscopic procedures were associated with HCV infection (175–
178). Other clinical studies monitored HCV-negative patients
who underwent GI endoscopy with the same endoscopes as those
used on HCV-positive patients (179, 180). It was concluded that
the risk forHCV transmission by endoscopy is lowwhen adequate
endoscope reprocessing is used.
Several cases of patient-to-patient HCV transmission have
been related to inadequate cleaning and disinfection of GI endo-
scopes and accessories (181–184) and to the use of contaminated
anesthetic vials or syringes (182, 183). In two cases, genotyping
and nucleotide sequencing of the viral isolates showed the same
HCV strain (181, 182).
Ciesek et al. (185) examined the sensitivity of HCV to hand
antiseptics, high-level disinfectants, and high temperatures. Glu-
taraldehyde (0.5%) and 0.05% peracetic acid were able to com-
pletely inactivate HCV within 1 min of incubation. A 100-fold
reduction of infectivitywas observed after 5min of exposure of the
virus to 75°C.
HIV. Recognition of the viral etiology of AIDS in 1983 led to
great concern about possible health care-associated transmission
of the virus. HIVmight be inoculated during trauma into GI mu-
cosa, for example, during insertion of a contaminated endoscope.
No cases of HIV transmission attributed to endoscopy have
been reported so far. The virus is sensitive to many disinfectants,
including 70% ethanol and 2% glutaraldehyde (186). Sampling of
20 gastroscopes immediately after use in patients with AIDS and
before disinfection found contamination with commensal bacte-
ria, P. aeruginosa, Candida albicans, HBV, and, in 35% of cases,
HIV (187). Bronchoscopes were less heavily contaminated: HIV,
HBV, commensal bacteria, and Pneumocystis jirovecii were de-
tected by culturing, immunofluorescence tests, and PCR after
bronchoscopy of patients with pulmonarymanifestations of AIDS
(187). Disinfection with 2% glutaraldehyde for 2 min completely
eliminated HIV from the endoscopes artificially contaminated
with high levels of virus (188).
Enteroviruses. Enteroviruses are nonenveloped viruses that are
more resistant to chemical disinfectants than enveloped viruses.
No cases of endoscopic transmission of enteroviruses have been
reported. Narang and Codd (189) found that 2% glutaraldehyde
reduced poliovirus titers by at least 6 logs within a 30-min test
period. Hanson et al. (190) studied elimination of enterovirus by
2% glutaraldehyde from endoscopes artificially contaminated
with high virus levels. Samples were virus free after 2 min of dis-
infection. Virus dried on surfaces was inactivated in 1 min by 2%
glutaraldehyde, with a reduction of 6 logs. Thus, disinfection
was effective against a heavy contamination of endoscopes with
enterovirus.
Kovaleva et al.
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Creutzfeldt-Jakob Disease (Prion Disease)
Creutzfeldt-Jakob disease (CJD) and other transmissible spongi-
form encephalopathies are lethal degenerative neurological disor-
ders with symptoms including dementia, ataxia, myoclonus, and
pyramidal and extrapyramidal damage (191). These degenerative
encephalopathies are transmitted by infectious agents called pri-
ons (protein particles without nucleic acid) and are characterized
by accumulation and different distribution of the specific prion
protein in the human body. CJD occurs in new-variant and clas-
sical (sporadic and iatrogenic) forms. Iatrogenic CJD followed
administration of cadaveric human pituitary hormones (192,
193), dural graft transplants (194), corneal transplants (195), and
the use of contaminated neurosurgical instruments (196).
In classical CJD, prion protein is concentrated in the central
nervous system and is found less often in other organs (191).
Intestinal tissue, blood, and saliva have a low risk for transmission
of classical CJD. In new-variant CJD, large amounts of the prion
protein are accumulated in lymphoid tissue, including theGI tract
(197). Therefore, new-variant CJD transmission via a GI endo-
scopic procedure remains theoretically possible (198), but no re-
ports of such transmission have been noted in the literature (199).
Prions are highly resistant to routine methods of decontamina-
tion and sterilization and can remain infectious for years (200).
Dry heat, glutaraldehyde, and ethylene oxidewere concluded to be
ineffective disinfection and sterilization methods for medical de-
vices (201, 202). Recommended chemical methods include a de-
contamination stepwith concentrated sodiumhydroxide, sodium
hypochlorite, or formic acid and prolonged steam sterilization
(200, 203, 204). Most contemporary flexible endoscopes cannot
be heat sterilized and disinfected with high concentrations of dis-
infectants without severe damage (1, 9). Therefore, flexible endo-
scopes should be discarded after endoscopy in patients with CJD
(205).
ENDOGENOUS INFECTION ASSOCIATED WITH FLEXIBLE
ENDOSCOPY
Flexible Gastrointestinal Endoscopy
Diagnostic and therapeutic upper gastrointestinal endoscopy.
Bacteremia occurs when the mucosal membrane is damaged (for
example, during tooth cleaning). Microscopic tissue trauma oc-
curring during endoscope insertion can result in transient bacte-
remia. In this case, microorganisms isolated from blood cultures
belong to the oropharyngeal commensal microflora and are gen-
erally of low pathogenicity (206).
The reported incidence of bacteremia after diagnostic upperGI
endoscopy, with or without biopsies, was less than 8% (207–215).
The isolated microorganisms included mainly Staphylococcus epi-
dermidis and Streptococcus spp. No infectious complications were
detected in patients with bacteremia in a follow-up study 6
months to 2 years after endoscopy.
Therapeutic upperGI endoscopy, including esophageal sclero-
therapy, variceal ligation, and esophageal dilatation, is associated
with significantly more tissue trauma than diagnostic endoscopy
(216). These endoscopic procedures are frequently performed in
the setting of acute bleeding or a benign or malignant stricture of
the esophagus and have a higher rate of bacteremia (30%) than
diagnostic endoscopic procedures (12.5%) (214). The incidence
of transient bacteremia ranges from 0% to 53% after esophageal
sclerotherapy (65, 217–225), from 1% to 25% after endoscopic
variceal ligation (211, 217, 219, 226), and from 2% to 54% after
esophageal dilatation (227–230).
Other reported infectious complications after upper GI endos-
copy include endocarditis of native and prosthetic valves (231–
239), meningitis and/or cerebral abscess (240–245), and bacterial
peritonitis (222, 246, 247). The majority of isolated organisms
were Streptococcus viridans and Staphylococcus spp.
Colonoscopy and sigmoidoscopy. Microorganisms found in
the colon include anaerobic bacteria (Bacteroides fragilis andClos-
tridium spp.), Enterobacteriaceae (E. coli, Klebsiella spp., Entero-
bacter spp., andProteus spp.), and enterococci (248). The reported
incidence of bacteremia after colonoscopy, with or without biop-
sies and polypectomies, ranges from 0% to 25% (249–257). In
immunocompetent patients, bacteremia during or after lower GI
endoscopic procedures is usually transient and asymptomatic.
Duration of colonoscopy with or without biopsy and/or polypec-
tomydoes not appear to increase the rate of bacteremia (253, 254).
The incidence of transient bacteremia after flexible sigmoidos-
copy ranges from 0% to 1% (258–260).
Other infectious complications after colonoscopy and sig-
moidoscopy include acute appendicitis (261–267), bacterial peri-
tonitis (268, 269), endocarditis (270–273), and septicemia (274–
277). Two cases of Listeria monocytogenes meningitis and
septicemia (278, 279) and one case of Fournier’s gangrene of the
perineum have been described (280). The most commonly iso-
lated microorganisms are enterococci, Enterobacteriaceae, and
Bacteroides spp.
Percutaneous endoscopic gastrostomy. The most common
complication of percutaneous endoscopic gastrostomy is peristo-
mal wound infection, with the rate varying between 3% and 32%
(281–286). The high risk of wound infection can be explained by
contamination of the wound with oropharyngeal microflora dur-
ing placement of a tube. More severe complications include ne-
crotizing fasciitis (287–289), abdominal abscess, peritonitis, and
septicemia (281, 290–295). The most common infecting organ-
isms are Staphylococcus aureus, Gram-negative bacteria (Klebsiella
spp., Enterobacter spp., and P. aeruginosa), enterococci, and C.
albicans (291, 295).
Endoscopic retrograde cholangiopancreaticography.ERCP is
an endoscopic procedure associated with an incidence of severe
infectious complications of between 2% and 4%, including sepsis,
ascending cholangitis, liver abscess, acute cholecystitis, and in-
fected pancreatic pseudocyst (296–299). A complication of ERCP
can be defined as any event following the 30-day period after en-
doscopy that changed the health status of a patient negatively
(300). Post-ERCP complications can be divided intomild (up to 3
days in the hospital), moderate (4 to 10 days of hospitalization),
and severe (more than 10 days of hospitalization, surgical inter-
vention, and/or death) complications. The important risk factors
for post-ERCP infections are exogenous (because of contamina-
tion of endoscopes and accessory equipment) and endogenous
patient-related factors, including obstruction of the bile or pan-
creatic duct, tissue damage during the procedure, and compro-
mised immune status (2, 18, 75, 81, 99).
The rate of occurrence of bacteremia ranges from 0% to 15%
after ERCP of unobstructed pancreatic or bile ducts (96, 301–304)
and from 0% to 27% in patients with biliary obstruction by stones
or a tumor (302–307). Not all bacteremic episodes result in a
clinically relevant complication. ERCP-related sepsis is one of the
most serious complications of this procedure, with a reported
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mortality rate as high as 29.4% despite the use of antibiotic ther-
apy (307). The incidence of post-ERCP sepsis varies from 0.25%
to 5.4% in different patient populations (296, 305, 308–311) and is
significantly higher in patients with malignant biliary obstruction
than in those with benign obstruction (21% versus 3%) (312).
Ascending cholangitis results mainly from inadequate drain-
age of an infected and obstructive biliary duct system (96). The
rate of cholangitis after ERCP varies from 0.08% to 5% (296–299,
313–322). Post-ERCP cholangitis is defined by a typical clinical
picture (temperature of 38°C, upper abdominal colicky pain,
and cholestasis/jaundice) without evidence of other concomitant
infections andwith or without positive bile cultures obtained dur-
ing biliary drainage (299). The most frequent organisms respon-
sible for cholangitis/sepsis are enteric bacteria, including Entero-
bacteriaceae (E. coli, Klebsiella spp., and Enterobacter spp.),
enterococci, and a variety of species of alpha-hemolytic strepto-
cocci (302, 306, 323).
Post-ERCP cholangitis is also a frequent complication of a bil-
iary endoprosthesis insertion and occluded stents (323). Thus,
stent removal and replacement frequently occur as a consequence
of blockage caused by biofilm growth in the stent lumen (324).
Enterococci, the most common organisms identified from pa-
tients with stents, are frequently isolated from infected bile in
association with other microorganisms (323). Leung et al. (325)
demonstrated a synergism between E. coli and enterococcal infec-
tion: colonization of a stent with E. coli facilitated attachment and
biofilm formation by enterococci.
Other post-ERCP infectious complications include acute cho-
lecystitis, with incidences ranging from 0.1% to 5.9% (296–299,
314, 321, 326, 327); liver abscess (296, 298, 328, 329); and infec-
tion of pancreatic pseudocysts (297, 314).
Antibiotic prophylaxis inflexible gastrointestinal endoscopy.
The purpose of antibiotic prophylaxis during GI endoscopy is to
reduce the risk of iatrogenic infectious complications. Prophylac-
tic antibiotic administration is not recommended for all GI endo-
scopic procedures (330). Therapeutic ERCP, percutaneous endo-
scopic gastrostomy, esophageal sclerotherapy, variceal ligation,
and esophageal dilatation are endoscopic procedures associated
with the highest rates of bacteremia and other infectious compli-
cations (216). Regimens of antibiotic prophylaxis for GI endo-
scopic procedures are summarized in Table 6.
Percutaneous endoscopic gastrostomy is associatedwith a high
risk of development of wound infection at the gastrostomy site
(331). Prophylactic administration of antibiotics reduced the rel-
ative and absolute risk of wound infection by 73% and 17.5%,
respectively, and is recommended for all patients undergoing per-
cutaneous endoscopic gastrostomy (285, 331). The American So-
ciety for Gastrointestinal Endoscopy (ASGE) and the Endoscopy
Committee of the British Society of Gastroenterology recommend
antibiotic prophylaxis with an antibiotic that provides coverage of
cutaneous microorganisms, such as a narrow- or expanded-spec-
trum cephalosporin or amoxicillin-clavulanate, for patients un-
dergoing percutaneous endoscopic gastrostomy, 30 min before
the procedure (332, 333).
TABLE 6 Antibiotic prophylaxis recommended for gastrointestinal endoscopya
Type of gastrointestinal endoscopic procedure and
patient condition Goal of prophylaxis Prophylaxis
Percutaneous endoscopic gastrostomy Prevention of peristomal infection Cefazolin 1-g i.v. single dose 30 min before procedure,
cefuroxime 1.5-g i.v. single dose, or amoxicillin-
clavulanate 1.2-g i.v. single dose
Esophageal sclerotherapy, variceal ligation Prevention of procedure-related
bacteremia and peritonitis
Piperacillin-tazobactam 4.5-g i.v. single dose (some
give 3 times daily), cefotaxime 2-g i.v. single dose,
or ceftriaxone 2-g i.v. single dose
Cirrhosis with acute variceal bleeding
Esophageal dilatation
Benign/malignant stricture of the esophagus
Endoscopic retrograde cholangiopancreaticography
Biliary obstruction (e.g., primary sclerosing
cholangitis and/or hilar cholangiocarcinoma)
when complete biliary drainage is unlikely to
be achieved
Prevention of cholangitis Ciprofloxacin 750-mg single dose orally 1.5–2 h
before procedure, piperacillin-tazobactam 4.5-g i.v.
single dose 1 h before procedure, or i.v. single dose
of gentamicin at 1.5 mg/kg of body weight at time
of sedation
Communicating pancreatic cysts/pseudocysts Prevention of cyst infection See above (“Biliary obstruction”)
Biliary complications after liver transplantation Prevention of cholangitis Ciprofloxacin 750-mg single dose orally 1.5–2 h
before procedure, gentamicin 1.5-mg/kg i.v. single
dose at the time of sedation plus amoxicillin 1-g i.v.
single dose, or vancomycin at 20 mg/kg i.v. over at
least 1 h
Any gastrointestinal endoscopic procedure
Patients with cardiovascular risk factors Prevention of infective endocarditis Not recommended
Patients with synthetic vascular graft and other
cardiovascular devices
Prevention of graft and device infection Not recommended
Patients with prosthetic joints Prevention of septic arthritis Not recommended
a Data are based on the guidelines of antibiotic prophylaxis for gastrointestinal endoscopy of the American Society of Gastrointestinal Endoscopy (332) and the Endoscopy
Committee of the British Society of Gastroenterology (333). i.v., intravenous.
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Therapeutic upperGI endoscopic procedures associatedwith a
high rate of postprocedure bacteremia and peritonitis include
esophageal sclerotherapy, variceal ligation, and esophageal dilata-
tion. Prophylactic administration of antibiotics is recommended
for all patients with cirrhosis and acute variceal bleeding before
esophageal sclerotherapy and variceal ligation and for patients
with benign or malignant esophageal strictures before esophageal
dilatation (333). A recent meta-analysis of 12 trials indicated a
significant beneficial effect of antibiotic prophylaxis compared
with placebo and no prophylaxis in decreasing the incidence of
bacterial infections, bacteremia, pneumonia, spontaneous perito-
nitis, and mortality from bacterial infections in cirrhotic patients
with GI bleeding (334). These benefits were observed indepen-
dently of the antibiotic used. Administration of a broad-spectrum
cephalosporin or piperacillin-tazobactam in a single dose or three
doses during 1 day is recommended by the ASGE and the British
Society of Gastroenterology (332, 333).
Recent studies examining antibiotic prophylaxis prior to ERCP
concluded that it may reduce the incidence of bacteremia but did
not reduce the incidence of clinical sepsis or cholangitis, and
therefore, routine use of antibiotic prophylaxis cannot be recom-
mended (300, 335, 336). Antibiotic prophylaxis is recommended
before an ERCP in patients with biliary obstruction (e.g., primary
sclerosing cholangitis and/or hilar cholangiocarcinoma) when
complete biliary drainage is unlikely to be achieved and in patients
with communicating pancreatic cysts or pseudocysts for preven-
tion of cyst infection (332, 333). An adequate biliary drainage will
prevent postprocedure cholangitis or sepsis without prophylactic
administration of antibiotics. Continuation of antibiotics after
ERCP in patients with biliary complications after liver transplan-
tation may be beneficial, even when drainage is achieved (332,
333). Prophylactic antibiotics should cover biliary flora such as
Enterobacteriaceae, Bacteroides spp., P. aeruginosa, and entero-
cocci. An optimumbenefit of antibiotics is obtained if therapeutic
levels are present in the tissues at the time of the endoscopic pro-
cedure. Antibiotic prophylaxis should be started orally or intrave-
nously at least 1 to 2 h before the procedure. Oral ciprofloxacin,
intravenous piperacillin-tazobactam, or gentamicin is recom-
mended (332, 333). Increasing microbial resistance (ciprofloxa-
cin), poor penetration into bile (gentamicin), and limited activity
against enterococci (gentamicin and ciprofloxacin) are disadvan-
tages of these antibiotics. According to the British Society of Gas-
troenterology, for patients undergoing ERCP with biliary compli-
cations after liver transplantation, these antibiotics should be
combined with amoxicillin or vancomycin to target Enterococcus
spp. (333). However, local incidence of amoxicillin-resistant, van-
comycin-sensitive enterococci and known colonization with van-
comycin-resistant enterococci need to be considered. In hospitals
with an increasing frequency of vancomycin-resistant entero-
cocci, teicoplanin is recommended in preference to vancomycin
for two reasons: first, it is simpler and quicker to administer, and
second, more sustained blood levels occur following a single dose
(337).
Antibiotic administration for prevention of infective endocar-
ditis (in patients with cardiovascular risk factors) and graft and
device infections (in patients with synthetic vascular graft and
other cardiovascular devices) before GI endoscopy is no longer
recommended by the ASGE and the American Heart Association
(332, 338). This recommendation is based on an absence of clin-
ically significant evidence of infective endocarditis and device in-
fection being associated with GI procedures and on an absence of
a conclusive link between GI endoscopy and development of any
other type of infection (332). Antibiotic prophylaxis of septic ar-
thritis duringGI endoscopy is not recommended for patients with
orthopedic prostheses. However, prophylactic antibiotic admin-
istration can be considered prior to any therapeuticGI endoscopic
procedure in patients with a seriously impaired immune status
(e.g., in cases of neutropenia and hematological malignancy)
(333).
Flexible Bronchoscopy
Oropharyngeal microorganisms from the upper respiratory tract
can be carried down into the lower respiratory tract during inser-
tion of a bronchoscope into the lung through the mouth and can
penetrate into the bloodstream. These microorganisms include
viridans group streptococci, staphylococci, Moraxella spp., Neis-
seria spp., and anaerobic bacteria (103).
Bacteremia following bronchoscopy, with or without biopsy, is
transient and occurs in5% of patients (339–343). Themicroor-
ganisms most frequently isolated from positive blood cultures are
staphylococci and beta-hemolytic and viridans group strepto-
cocci, which are part of the normal upper airway flora. Fever after
bronchoscopic procedures has been reported inmany studieswith
a wide range of frequencies, from 0% to 27% (341, 343–349).
Reported fevers were transient, developed during the first day af-
ter bronchoscopy, and were not associated with septic complica-
tions. One possible mechanism of development of fever after
bronchoscopy is the release of proinflammatory cytokines from
alveolar macrophages (350).
Pneumonia following bronchoscopic procedures has been re-
ported, with a frequency of 0.6% to 6% (345, 346). Postbroncho-
scopy pneumonia was defined as the development of fever and a
new or progressive infiltrate on a chest radiographwith peripheral
leukocytosis and elevated levels of the C-reactive protein after the
procedure. Several cases of fatal pneumonia, long abscess, and
sepsis following bronchoscopy with isolation of Streptococcus
pneumoniae, E. coli,Haemophilus influenzae, and Cryptococcus sp.
from positive blood cultures and bronchial specimens have been
described (351–355).
Antibiotic prophylaxis is not recommended during flexible
bronchoscopy with or without biopsy because of the low inci-
dence of bacteremia and endocarditis (356, 357). Only one case
report of infective endocarditis following bronchoscopy in an
HIV-positive patient with mitral valve prolapse has been pub-
lished (358). The American Heart Association does not recom-
mend antibiotic prophylaxis for routine flexible bronchoscopy
(357). However, administration of 2.0 g amoxicillin orally 1 h
prior to bronchoscopy is recommended for rigid bronchoscopy,
particularly for high-risk patients, including patients with pros-
thetic cardiac valves, previous bacterial endocarditis, and complex
cyanotic congenital heart disease (e.g., tetralogy of Fallot) (357).
The British Thoracic Society Bronchoscopy Guidelines Commit-
tee recommends prophylactic administration of antibiotics before
bronchoscopy for patients who are asplenic, have a heart valve
prosthesis, or have a history of endocarditis (356).
IMPACT OF BIOFILM ON ENDOSCOPE REPROCESSING
Microorganisms in nature do not generally grow in nutrient-rich
suspensions (the so-called planktonic state) as in the laboratory
but prefer to grow in surface-associated communities called bio-
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films. A biofilm is an assemblage of microbial cells that is irrevers-
ibly attached to a surface and enclosed in amatrix of exopolymeric
substances (359). A typical biofilmwill contain around 85% poly-
meric substances and only 15% bacterial mass, and cells are lo-
cated in matrix-enclosed “towers” and “mushrooms” (Fig. 2)
(360, 361). Biofilms may form on different surfaces, including
living or dead tissues, medical devices, water supply systems, or
endoscope channels (89, 359). Biofilm formation by microorgan-
isms on inert surfaces has been extensively studied, and there is a
direct relationship between the ability of the organism to form a
biofilm and its pathogenicity (362). Many bacteria, including P.
aeruginosa and atypical mycobacteria, are capable of existing in a
planktonic state and can produce biofilms.
Bacteria growing within biofilms have a number of character-
istics that distinguish them from planktonic populations. The
ability to form biofilms allows microorganisms to survive under
conditions of drying and chemical and antibiotic exposure (363,
364). Microorganisms in biofilms are protected from the host im-
mune system andmay be 1,000 timesmore resistant to antibiotics
than planktonic cells (365). The increased resistance to antimicro-
bial agents can be explained by poor penetration of an antibiotic
into a biofilm, low growth rate, and formation of resistant pheno-
types of microorganisms within biofilms (363, 364).
Under adverse conditions, biofilms are capable of releasing
their bacterial population into a planktonic state. This ability can
be explained by intercellular communication within a biofilm
(366). Signaling systems include quorum sensing (the release of
chemical signals in response to increasing population density),
biosignal blockers, pheromones, and butyrylhomoserine lactone.
These signaling systems are important for regulation of a number
of physiological processes, including antibiotic synthesis, plasmid
transfer, and expression of virulence factors (367).
During endoscopy, the environment provides optimal condi-
tions for contamination and subsequent growth of biofilms.Mod-
ern flexible endoscopes contain multiple channels and ports
which can easily collect organic material. Even if valid endoscope
reprocessing protocols are applied, microbial accumulation can
lead to development of a biofilm inside narrow endoscope chan-
nels over time (89). Biofilm formation on the inner surface of
endoscope channels, especially when these become scratched or
damaged, can result in failure of the decontamination process. It
can create a vicious circle of growth, disinfection, partial killing or
inhibition, and regrowth, resulting in outbreaks of endoscopy-
related infections in patients who underwent endoscopy with a
biofilm-containing endoscope (2, 3).
The presence of biofilms on the inner surface of endoscope
channels has been reported in the literature (2, 89). Anoutbreak of
post-ERCP sepsis with multiresistant P. aeruginosa was related to
biofilm development inside endoscope channels (2). Three out-
breaks of postendoscopic infection and cross-contaminationwere
attributed to contaminated AERs with the presence of biofilm
deposits on the internal plumbing and detergent tank (23, 25, 26).
Cross-contaminations of M. chelonae and M. mesophilicum re-
sulted in colonization of patients after endoscopy with no infec-
tious complications (25). Reported infections in two other out-
breaks included post-ERCP P. aeruginosa bacteremia/sepsis and
cholangitis (23) and sepsis and pneumonia after bronchoscopy
(26).
Biofilms can be removed from artificial surfaces by physical
and chemical methods (368). Physical methods such as ultra-
sound and manual cleaning are generally effective but difficult to
control in practice. Chemical methods can be unsuccessful be-
cause of the resistance of biofilms to antibiotics, disinfectants, and
biocides (363). The cleaning process is most critical for biofilm
removal becausemultiple internal channels of flexible endoscopes
cannot be inspected for cleanliness. The cleaning product must
show good penetration and solubilization of organic debris and
biofilms. In a study reported by Vickery et al. (368), enzymatic
cleaners failed to reduce viable bacterial numbersmore than 2 logs
in E. coli biofilms in polyvinyl chloride tubing. Another study
reported the failure of a commonly used enzymatic cleaner to
completely remove test soil from endoscope channels (369). Non-
enzymatic detergents showed a better inhibition of biofilm forma-
tion than enzymatic detergents (368, 370). The most efficient
methods for biofilm removal were autoclaving and treatmentwith
a concentrated bleach solution (49). High-temperature treat-
ments (80°C to 90°C) were not effective for biofilm removal.
The use of antibiofilm-oxidizing agents with an antimicrobial
coating inside washer disinfectors could reduce biofilm buildup
inside endoscopes and AERs and decrease the risk of transmitting
infections (15, 49). Sterilization can be helpful to destroy micro-
organisms within biofilms. However, ethylene oxide sterilization
may fail in the presence of organic debris after an inadequate
cleaning procedure before reprocessing of flexible endoscopes
(16, 17).
MICROBIOLOGICAL SURVEILLANCE OF ENDOSCOPE
REPROCESSING
Routine microbiological testing for endoscopes and AERs re-
mains a controversial issue in many guidelines. Microbiological
surveillance of endoscope reprocessing has been recommended by
several medical specialist organizations (371–373). It is appropri-
ate to trace contaminations of endoscopes and to prevent contam-
inations and infections in patients after endoscopic procedures (2,
3). The use of environmental endoscope culturing is a rapid and
simplemethod tomonitor the effectiveness of standard reprocess-
ing procedures (374). Other organizations recommend microbi-
ological surveillance of flexible endoscopes only in response to
epidemiologic investigations when instruments may be microbial
sources of health care-associated disease transmission or in the
case of testing the effectiveness of new or modified cleaning or
disinfection procedures (375). Microbiological surveillance sys-
FIG 2 A mature biofilm in a flowing environment comprises a complex
mushroom-shaped architecture, long streamers, and water channels which
permit the bulk fluid to penetrate deepwithin the biofilm, carrying oxygen and
nutrients. (Courtesy of MSU Center for Biofilm Engineering, P. Dirckx; re-
printed with permission.)
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tems have several important limitations. If there is a clinical de-
mand for the reuse of an endoscope, surveillance culture results
will not be obtained until after the endoscope is used on the next
patient, because culture results take aminimumof 24 to 48 h to be
produced (371). Efficient sampling of flexible endoscopes and
their accessories may be hindered by a complex design, materials,
construction, and fragility or by the absence of a standardized
sampling protocol or an appropriate technique for sampling of the
surfaces and channels of the flexible endoscope (375).
Some techniques are recommended for microbiological sam-
pling of flexible endoscopes (375). A swab-rinse technique should
be used for sampling the exterior surfaces and the distal opening of
the suction-biopsy channel port. For adequate sampling of the
inferior surface of endoscope channels, a “flush/brush/flush”
technique should be performed with rinsing through the channel
with a sterile fluid and using a sterile cleaning brush to obtain
samples from the biopsy port. A simple flushthrough technique
may be considered when brushing of the channel lumens is im-
possible, but it is less efficient (375).
According to the literature, endoscopes can be sampled in an
anterograde and retrograde manner. For anterograde sampling,
the last-rinse water from the endoscope is collected inside the
washer-disinfector at the distal end of the endoscope (3, 9). For
retrograde sampling, the suction-biopsy channel and the air-wa-
ter channel of the endoscope are each flushed with 20 ml sterile
demineralized water manually outside the AER from the distal to
the proximal end. According to the literature, anterograde sam-
pling is not sensitive enough (3, 9). Endoscope culturing with a
retrograde technique is effective formonitoring endoscope repro-
cessing, and testing is easy to perform (3). Introduction of new
techniques that are easier to perform on a daily basis and with
faster results may improve the microbiological surveillance of en-
doscope reprocessing. New methods may be based on direct ATP
measurement or quantitative PCR. These methods must be fur-
ther optimized because of their low specificity (376, 377).
The literature provides no standards for the frequency of test-
ing intervals of surveillance cultures. The Gastroenterological So-
ciety of Australia guideline recommends microbiological moni-
toring of duodenoscopes, bronchoscopes, andAERs every 4weeks
and all other GI endoscopes every 4 months (372). According to
the European Society of Gastrointestinal Endoscopy guideline,
routinemicrobiological testing of endoscopes is advised to be per-
formed at intervals of no longer than 3 months (371). The use of
routine environmental microbiological testing of therapeutic en-
doscopes once a month and diagnostic endoscopes once every 3
months has been reported (2, 3).
A contaminated endoscope should be inspected for potential
defects. Unfortunately, it is not possible to adequately check all
internal endoscope channels. Any small damage can be the source
of bacterial contamination within the scope, which is difficult or
impossible to detect by routine inspection and testing (2, 3). Some
investigators have begun to explore sterile-sheathed endoscopes
with new technology to reduce the risk of infectious complications
(9, 378). The EndoSheath, for instance, is an endoscope system in
which all parts of the endoscope that come into contact with the
patient are fully disposable.
Literature related to the costs associatedwith endoscope repro-
cessing and economic consequences of endoscope contamination
is very limited. Economic evaluation of exogenous endoscopy-
related outbreaks should include an analysis of outcomes (num-
ber of prevented iatrogenic infections) and an estimation of the
health care, non-health care, and indirect costs (78). A recently
reported study analyzed the cost of 4-weekly surveillance micro-
biological tests of bronchoscopes, duodenoscopes, and AERs dur-
ing a 5-year period (379). The overall annual cost of microbiolog-
ical testing and cost in time for nursing staff to collect the samples
was estimated to be $13,339. Another study calculated the annual
costs of surveillance of endoscope reprocessing (cost of microbi-
ological testing and cost in time for staff) to be $33,959 (18). It was
also estimated that the cost of the post-ERCP outbreak of P.
aeruginosa sepsis affecting six patients, i.e., direct health care costs
for diagnosis, treatment, and hospitalization of six affected pa-
tients, was approximately $206,273 (18).
CONCLUSION
Contaminated endoscopes have been linked tomany outbreaks of
device-related nosocomial infections. The true incidence of en-
doscopy-related infections is unknownbecause of inadequate sur-
veillance or no surveillance at all. Endoscopy-related infections
can cause serious harm and can give rise to concerns over these
procedures by physicians and patients. Flexible endoscopes can be
cleaned and disinfected but not sterilized after use. This implies
the risk of settlement of biofilm-producing species.
Process control of the cleaning and disinfection procedure
does not guarantee prevention of biofilm formation during en-
doscopy. Implementation of microbiological surveillance of en-
doscope reprocessing is appropriate to detect early colonization
and biofilm formation in the endoscope and to prevent contami-
nation and infection in patients after endoscopic procedures.
However, the returns of prevention of endoscopy-related infec-
tions should be reasonably in balance with costs of technical and
laboratory procedures resulting from surveillance and the costs of
reprocessing or servicing of the contaminated endoscope.
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